Pharmaceutical Executive, Feb 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Feb 1, 2013
Features
Oncology: Pathways to Progress
By William Looney
Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.
Turkey: A Promise Restored?
By Julian Upton
After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.
Rethinking Product Lifecycle Management
By Stan Bernard, MD
"Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard.
Country Report
Country Report: Australia
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally: the country is dealing with patent cliffs, companies are cutting back staff, an ageing population forces the government to rethink healthcare expenditures, and big originator companies are reforming.
Column
Fortuity and the First Amendment
By Thomas R. Julin , Jamie Z. Isani , Patricia Acosta
Caronia decision shows the staying power of Sorrell v. IMS Health.
Breakthrough Year for New Drugs
By Jill Wechsler
More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.
NHTSA Addresses "Drugged Driving"
By Ben Comer
After years of asking questions, the National Highway Traffic Safety Administration (NHTSA)is moving closer to a protocol "for assessing the driving-impairment risks of drugs". Ben Comer reports.
From the Editor
In Cancer, Process Drives Progress
By William Looney
Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.

ADVERTISEMENT

Click here